# Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

> **NCT02348203** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 63 (actual)

## Conditions studied

- Tobacco Use Disorder

## Interventions

- **DRUG:** Aspirin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **OTHER:** Placebo Administration
- **DRUG:** Zileuton

## Key facts

- **NCT ID:** NCT02348203
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-13
- **Primary completion:** 2019-02-22
- **Final completion:** 2021-03-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348203, "Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02348203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*